Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 19

1.

Succinamide derivatives of melampomagnolide B and their anti-cancer activities.

Janganati V, Ponder J, Thakkar S, Jordan CT, Crooks PA.

Bioorg Med Chem. 2017 Jul 15;25(14):3694-3705. doi: 10.1016/j.bmc.2017.05.008. Epub 2017 May 8.

PMID:
28545815
2.

Indole carboxylic acid esters of melampomagnolide B are potent anticancer agents against both hematological and solid tumor cells.

Bommagani S, Ponder J, Penthala NR, Janganati V, Jordan CT, Borrelli MJ, Crooks PA.

Eur J Med Chem. 2017 Aug 18;136:393-405. doi: 10.1016/j.ejmech.2017.05.031. Epub 2017 May 11.

PMID:
28525840
3.

Identification of a melampomagnolide B analog as a potential lead molecule for treatment of acute myelogenous leukemia.

Albayati ZAF, Janganati V, Chen Z, Ponder J, Breen PJ, Jordan CT, Crooks PA.

Bioorg Med Chem. 2017 Feb 1;25(3):1235-1241. doi: 10.1016/j.bmc.2016.12.036. Epub 2016 Dec 26.

PMID:
28049618
4.

Reactivity of Biliatresone, a Natural Biliary Toxin, with Glutathione, Histamine, and Amino Acids.

Koo KA, Waisbourd-Zinman O, Wells RG, Pack M, Porter JR.

Chem Res Toxicol. 2016 Feb 15;29(2):142-9. doi: 10.1021/acs.chemrestox.5b00308. Epub 2016 Jan 13.

5.

Dimers of Melampomagnolide B Exhibit Potent Anticancer Activity against Hematological and Solid Tumor Cells.

Janganati V, Ponder J, Jordan CT, Borrelli MJ, Penthala NR, Crooks PA.

J Med Chem. 2015 Nov 25;58(22):8896-906. doi: 10.1021/acs.jmedchem.5b01187. Epub 2015 Nov 16.

6.

Synthesis and antileukemic activities of C1-C10-modified parthenolide analogues.

Kempema AM, Widen JC, Hexum JK, Andrews TE, Wang D, Rathe SK, Meece FA, Noble KE, Sachs Z, Largaespada DA, Harki DA.

Bioorg Med Chem. 2015 Aug 1;23(15):4737-45. doi: 10.1016/j.bmc.2015.05.037. Epub 2015 May 30.

7.

Targeting the Ataxia Telangiectasia Mutated-null phenotype in chronic lymphocytic leukemia with pro-oxidants.

Agathanggelou A, Weston VJ, Perry T, Davies NJ, Skowronska A, Payne DT, Fossey JS, Oldreive CE, Wei W, Pratt G, Parry H, Oscier D, Coles SJ, Hole PS, Darley RL, McMahon M, Hayes JD, Moss P, Stewart GS, Taylor AM, Stankovic T.

Haematologica. 2015 Aug;100(8):1076-85. doi: 10.3324/haematol.2014.115170. Epub 2015 Apr 3.

8.

Dual targeting of the thioredoxin and glutathione antioxidant systems in malignant B cells: a novel synergistic therapeutic approach.

Kiebala M, Skalska J, Casulo C, Brookes PS, Peterson DR, Hilchey SP, Dai Y, Grant S, Maggirwar SB, Bernstein SH.

Exp Hematol. 2015 Feb;43(2):89-99. doi: 10.1016/j.exphem.2014.10.004. Epub 2014 Oct 22.

9.

Anti-cancer activity of carbamate derivatives of melampomagnolide B.

Janganati V, Penthala NR, Madadi NR, Chen Z, Crooks PA.

Bioorg Med Chem Lett. 2014 Aug 1;24(15):3499-502. doi: 10.1016/j.bmcl.2014.05.059. Epub 2014 May 27.

10.

Heterocyclic aminoparthenolide derivatives modulate G(2)-M cell cycle progression during Xenopus oocyte maturation.

Janganati V, Penthala NR, Cragle CE, MacNicol AM, Crooks PA.

Bioorg Med Chem Lett. 2014 Apr 15;24(8):1963-7. doi: 10.1016/j.bmcl.2014.02.067. Epub 2014 Mar 4.

11.

S-Nitrosation of monocarboxylate transporter 1: inhibition of pyruvate-fueled respiration and proliferation of breast cancer cells.

Diers AR, Broniowska KA, Chang CF, Hill RB, Hogg N.

Free Radic Biol Med. 2014 Apr;69:229-38. doi: 10.1016/j.freeradbiomed.2014.01.031. Epub 2014 Jan 30.

12.

Discovery of potent parthenolide-based antileukemic agents enabled by late-stage P450-mediated C-H functionalization.

Kolev JN, O'Dwyer KM, Jordan CT, Fasan R.

ACS Chem Biol. 2014 Jan 17;9(1):164-73. doi: 10.1021/cb400626w. Epub 2013 Nov 8.

13.

Parthenolide inhibits nociception and neurogenic vasodilatation in the trigeminovascular system by targeting the TRPA1 channel.

Materazzi S, Benemei S, Fusi C, Gualdani R, De Siena G, Vastani N, Andersson DA, Trevisan G, Moncelli MR, Wei X, Dussor G, Pollastro F, Patacchini R, Appendino G, Geppetti P, Nassini R.

Pain. 2013 Dec;154(12):2750-8. doi: 10.1016/j.pain.2013.08.002. Epub 2013 Aug 8.

14.

The redox proteome.

Go YM, Jones DP.

J Biol Chem. 2013 Sep 13;288(37):26512-20. doi: 10.1074/jbc.R113.464131. Epub 2013 Jul 16. Review.

15.

The cystine/glutamate antiporter regulates indoleamine 2,3-dioxygenase protein levels and enzymatic activity in human dendritic cells.

Mattox ML, D'Angelo JA, Grimes ZM, Fiebiger E, Dickinson BL.

Am J Clin Exp Immunol. 2012 Nov 30;1(2):113-123.

16.

Parthenolide reduces the frequency of ABCB5-positive cells and clonogenic capacity of melanoma cells from anchorage independent melanospheres.

Czyz M, Koprowska K, Sztiller-Sikorska M.

Cancer Biol Ther. 2013 Feb;14(2):135-45. doi: 10.4161/cbt.22952. Epub 2012 Nov 28.

17.

Extracellular glutathione decreases the ability of Burkholderia cenocepacia to penetrate into epithelial cells and to induce an inflammatory response.

D'Orazio M, Pacello F, Battistoni A.

PLoS One. 2012;7(10):e47550. doi: 10.1371/journal.pone.0047550. Epub 2012 Oct 19.

18.

Bcl-XL, but not Bcl-2, can protect human B-lymphoma cell lines from parthenolide-induced apoptosis.

Yeo AT, Porco JA Jr, Gilmore TD.

Cancer Lett. 2012 May 1;318(1):53-60. doi: 10.1016/j.canlet.2011.11.035. Epub 2011 Dec 6.

19.

The impact of redox and thiol status on the bone marrow: Pharmacological intervention strategies.

Grek CL, Townsend DM, Tew KD.

Pharmacol Ther. 2011 Feb;129(2):172-84. doi: 10.1016/j.pharmthera.2010.09.008. Epub 2010 Oct 15. Review.

Supplemental Content

Support Center